Table 2.
Predictive factors associated with FDG avidity
| Non-avid patients | PET-avid patients | UVA | ||
| n (%) | n (%) | P value | ||
| ECOG-PS1 | 0 | 9 (60) | 8 (40) | 0.58 |
| 1 | 5 (33) | 9 (47) | ||
| ≥ 2 | 1 (7) | 2 (11) | ||
| Gender | Female | 1 (7) | 8 (42) | 0.0474 |
| Male | 14 (93) | 11 (58) | ||
| Pathology-differentiation | Well | 10 (67) | 8 (42) | 0.311 |
| Moderate | 1 (7) | 5 (26) | ||
| Poor | 0 (0) | 1 (5) | ||
| Unknown | 4 (27) | 5 (26) | ||
| BCLC stage2 | A | 3 (20) | 1 (5) | 0.123 |
| B | 6 (40) | 4 (21) | ||
| C+ | 6 (40) | 14 (74) | ||
| Tumor burden | ≤ 50% | 14 (93) | 15 (79) | 0.3554 |
| > 50% | 1 (7) | 4 (21) | ||
| Portal vein thrombosis | No | 14 (93) | 15 (79) | 0.24 |
| Yes | 5 (33) | 10 (53) | ||
| Extrahepatic disease | No | 14 (93) | 17 (90) | 1.004 |
| Yes | 1 (7) | 2 (11) | ||
| Prior treatment | No | 9 (60) | 10 (53) | 0.67 |
| Yes | 6 (40) | 9 (47) | ||
| Child-Pugh-class | A | 14 (93) | 17 (90) | 1.004 |
| B | 1 (7) | 2 (11) | ||
| Viral hepatitis | No | 8 (53) | 14 (74) | 0.22 |
| Yes | 7 (47) | 5 (26) | ||
| Cirrhosis | No | 14 (93) | 16 (84) | 0.41 |
| Yes | 10 (67) | 10 (53) | ||
| Median (Range) | Median (Range) | |||
| Age | 59 (46-84) | 71 (57-84) | 0.10 | |
| PET SUV3 | 2(2-2) | 6(3-20) | - | |
| Initial AFP | 12 (1-478) | 16 (2-186000) | 0.23 | |
| Volume treated (mL) | 1260 (400-2044) | 1091 (191-2340) | 0.39 | |
| Dose delivered (Gy) | 125.9 (111.1-478.6) | 128.5 (110.5-467.5) | 0.66 |
1Eastern Cooperative Oncology Group Performance Status;
2
Barcelona Clinic Liver Cancer Staging classification;
3
Standardized uptake value;
4
Fisher’s exact test used. AFP: Alpha feto protein.